title: Control of cilostazol release kinetics and direction from a stent using a reservoir-based design.
abstract: Sustained release formulations of a potent antithrombotic drug, cilostazol, in poly-(lactic acid-co-glycolic acid) (PLGA) matrices were created for luminal release from a novel drug-eluting stent utilizing reservoirs (RES TECHNOLOGY™). The crystallinity of cilostazol and the morphology of the cilostazol/polymer matrix in the stent reservoirs were examined by cross-polarized optical microscopy and differential scanning calorimetry. An in vitro method was developed to study release kinetics of various cilostazol formulations and to examine correlation with in vivo release. Formulation parameters such as drug-to-polymer ratio and the use of a polymer barrier on the abluminal surface of the drug/polymer matrix were found to be effective in modulating drug release rate. Cilostazol/PLGA(75/25) in the weight ratio of 50/50 to 70/30 displayed first-order release kinetics for the majority of the drug load. Addition of an abluminal polymer barrier slowed cilostazol release rate when compared to the bidirectional reservoir design. Excellent correlation between cilostazol in vivo release profile from stents in a porcine coronary artery model and that measured in vitro in a modified USP-7 apparatus suggests that the in vitro release system is capable of predicting in vivo release of cilostazol from stent reservoirs.
authors.affiliation: Cordis Corporation, Johnson & Johnson Company and Affiliates, Fremont, California, USA. tedparker7@gmail.com
authors.forename: Theodore
authors.initials: T
authors.lastname: Parker
authors.forename: Vipul
authors.initials: V
authors.lastname: Davé
authors.forename: Robert
authors.initials: R
authors.lastname: Falotico
authors.forename: Jonathon
authors.initials: J
authors.lastname: Zhao
authors.forename: Thai
authors.initials: T
authors.lastname: Nguyen
authors.forename: Sylvia
authors.initials: S
authors.lastname: He
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Sun
authors.forename: Campbell
authors.initials: C
authors.lastname: Rogers
mesh_terms: D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000737:chemistry*; D000077407:Cilostazol; D020099:Coated Materials, Biocompatible / Q000493:pharmacokinetics*; D003331:Coronary Vessels / Q000601:surgery; D054855:Drug-Eluting Stents; D007700:Kinetics; D008422:Materials Testing; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics*; D013552:Swine; D013777:Tetrazoles / Q000737:chemistry / Q000493:pharmacokinetics*
chemical_list: D023181:Antimicrobial Cationic Peptides; D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; C045866:peptide-Gly-Leu-amide; D000077407:Cilostazol